News &amp; Updates

Asian women with polycystic ovary syndrome (PCOS) may have longer reproductive potential, with a high ovarian reserve that is maintained through older age and translates to increased success with assisted reproductive technology (ART) treatments, according to a retrospective study.

JAK inhibitor exposure affects response to ritlecitinib for alopecia areata

In patients with alopecia areata who received treatment with ritlecitinib, prior exposure to Janus kinase inhibitors is associated with reduced early response, reveals a study.

Does antibiotic use prevent wound complications in episiotomy, second-degree tear?

The use of prophylactic antibiotics shows no significant impact on overall wound complication but leads to a significant risk reduction in clinically relevant wound complications among women with episiotomies and second-degree tears, reports a study.

Is high-dose IV push levetiracetam safe to administer?

A recent study has provided further evidence on the safety and tolerability of rapid administration of undiluted levetiracetam, including 2,500- and 4,500-mg doses.

High-dose flu vaccine extends benefit to adults aged 50–64 years

A modified double-blind study shows the immunological superiority of high-dose (HD) over standard-dose (SD) inactivated influenza vaccine (IIV) in adults aged 50–64 years.

Acute kidney injury in preemies tied to poor neurodevelopmental outcomes

Preterm infants with acute kidney injury (AKI) may have poor neurodevelopmental outcomes, according to a study.

Enfortumab vedotin plus pembrolizumab confers survival benefit in MIBC

Adding perioperative enfortumab vedotin and pembrolizumab (EV + pembro) to surgery with radical cystectomy plus standard pelvic lymph node dissection (RC + PLND) significantly improves event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy, based on the first interim analysis of the phase III KEYNOTE-905 study presented at ESMO 2025.

Fixed-dose 4F-PCC safe, effective for FXal reversal in non-neurologic bleeds

A fixed-dose four-factor prothrombin complex concentrate (4F-PCC) demonstrates both safety and efficacy for factor Xa inhibitor (FXal) reversal in patients with non-neurologic haemorrhage, according to a recent study.

Updated CNS tumour epidemiology in Southeast Asia may guide future studies

18 Nov 2025 by

A study in Singapore has provided a comprehensive update of the epidemiology of brain and spinal tumours managed surgically, helping guide future research on central nervous system (CNS) tumours.

Accumulated daily steps in longer bouts tied to fewer mortality, CVD events

Daily accumulated steps in longer bouts appear to result in lower mortality and cardiovascular disease (CVD) risks than steps accumulated in shorter bouts among suboptimally active adults, reveals a study.